Bong originally joined Venrock in 2009 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).
Bong is a manager of Venrock’s public and cross-over biotech fund, Venrock Healthcare Partners, where he provides leadership in biotech investments.
On the private side, Bong led Avalanche Biotechnologies’ (NASDAQ: AAVL) series B financing and REGENXBIO’s series A round; furthermore he led Venrock’s series A investment in Juno Therapeutics (NASDAQ: JUNO) and its series B investment in Audentes Therapeutics.
Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.